Researchers from the National Cancer Institute and Stanford University have found that patients with primary mediastinal B-cell lymphoma can be treated successfully without radiation. The 51 patients in the study received a therapy regimen called dose-adjusted EPOCH-R, a combination of several chemotherapy drugs and the immunotherapy drug rituximab. All but 2 of the patients achieved a complete remission with this drug regimen, which means all signs and symptoms of the cancer disappeared in response to treatment. The other 2 achieved a complete remission after receiving radiation. Read more here.
Study mentioned: Kieron Dunleavy K, et al. Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. N Engl J Med 2013; 368:1408-1416.
No comments:
Post a Comment